Patents by Inventor John H. van Drie

John H. van Drie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS
    Publication number: 20210186961
    Abstract: Described herein are carboxamide derivatives that are useful as inhibitors of p90 ribosomal S6 kinase (RSK), pharmaceutical compositions comprising the derivatives, and methods of using the derivatives in treating diseases or conditions associated with RSK activity.
    Type: Application
    Filed: June 30, 2020
    Publication date: June 24, 2021
    Inventors: Sandra E. DUNN, Aarthi JAYANTHAN, Jaipal Reddy NAGIREDDY, Subhash ANNEDI, John H. VAN DRIE, Timothy S. DAYNARD, My-my HUYNH
  • Carboxamide derivatives useful as rsk inhibitors
    Patent number: 10758530
    Abstract: Described herein are carboxamide derivatives that are useful as inhibitors of p90 ribosomal S6 kinase (RSK), pharmaceutical compositions comprising the derivatives, and methods of using the derivatives in treating diseases or conditions associated with RSK activity. Such carboxamide derivatives form bicyclic and tricyclic ring systems and the disease or condition associated with RSK activity in a mammal is cancer.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: September 1, 2020
    Assignee: PHOENIX MOLECULAR DESIGNS
    Inventors: Sandra E. Dunn, Aarthi Jayanthan, Jaipal Reddy Nagireddy, Subhash Annedi, John H. Van Drie, Timothy S. Daynard, My-my Huynh
  • CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS
    Publication number: 20190134029
    Abstract: Described herein are carboxamide derivatives that are useful as inhibitors of p90 ribosomal S6 kinase (RSK), pharmaceutical compositions comprising the derivatives, and methods of using the derivatives in treating diseases or conditions associated with RSK activity. Such carboxamide derivatives form bicyclic and tricyclic ring systems and the disease or condition associated with RSK activity in a mammal is cancer.
    Type: Application
    Filed: February 17, 2017
    Publication date: May 9, 2019
    Inventors: Sandra E. DUNN, Aarthi JAYANTHAN, Jaipal Reddy NAGIREDDY, Subhash ANNEDI, John H. VAN DRIE, Timothy S. DAYNARD, My-my HUYNH
  • Substituted tetrahydropyrido[3?,2?:4,5]pyrrolo[1,2-?]pyrazine-2-carboxamides as RSK inhibitors
    Patent number: 10081632
    Abstract: Described herein are carboxamide derivatives of Formula (II) that are useful as inhibitors of p90 ribosomal S6 kinase (RSK), pharmaceutical compositions comprising the derivatives, and methods of using the derivatives in treating diseases or conditions associated with RSK activity: wherein R2, R4a, R4b, R11, R12, and n are defined in the specification.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: September 25, 2018
    Assignee: PHOENIX MOLECULAR DESIGNS
    Inventors: Sandra E. Dunn, Aarthi Jayanthan, Jaipal Reddy Nagireddy, Subhash Annedi, John H. Van Drie, Timothy S. Daynard, My-my Huynh
  • SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE
    Publication number: 20180193315
    Abstract: Compounds having a structure of Formula (IX): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1-Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.
    Type: Application
    Filed: February 28, 2018
    Publication date: July 12, 2018
    Inventors: Edward A. Kesicki, Arthur F. Kluge, Michael A. Patane, John H. Van Drie, JR., Ce Wang, Maricel Torrent, Michael L. Curtin, Todd M. Hansen, Rick F. Clark, Robin R. Frey, Zhiqin Ji, Yujia Dai, William J. McClellan, Jane Gong, Gui-dong G. Zhu, Anthony Mastracchio, Michael R. Michaelides, Thomas D. Penning, Chunqiu C. Lai
  • SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE
    Publication number: 20180071262
    Abstract: Compounds having a structure of Formula (IX): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.
    Type: Application
    Filed: October 6, 2017
    Publication date: March 15, 2018
    Applicant: AbbVie Inc.
    Inventors: Edward A. Kesicki, Arthur F. Kluge, Michael A. Patane, John H. Van Drie, JR., Ce Wang, Maricel Torrent, Michael L. Curtin, Todd M. Hansen, Rick F. Clark, Robin R. Frey, Zhiqin Ji, Yujia Dai, William J. McClellan, Jane Gong, Gui-dong G. Zhu, Anthony Mastracchio, Michael R. Michaelides, Thomas D. Penning, Chunqiu C. Lai
  • CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS
    Publication number: 20170327501
    Abstract: Described herein are carboxamide derivatives that are useful as inhibitors of p90 ribosomal S6 kinase (RSK), pharmaceutical compositions comprising the derivatives, and methods of using the derivatives in treating diseases or conditions associated with RSK activity.
    Type: Application
    Filed: July 31, 2017
    Publication date: November 16, 2017
    Inventors: Sandra E. DUNN, Aarthi JAYANTHAN, Jaipal Reddy NAGIREDDY, Subhash ANNEDI, John H. VAN DRIE, Timothy S. DAYNARD, My-my HUYNH
  • Substituted tetrahydropyrido[3?,2?:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors
    Patent number: 9771366
    Abstract: Described herein are carboxamide derivatives of Formula (II) that are useful as inhibitors of p90 ribosomal S6 kinase (RSK), pharmaceutical compositions comprising the derivatives, and methods of using the derivatives in treating diseases or conditions associated with RSK activity: wherein R2, R4a, R4b, R11, R12, and n are defined in the specification.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: September 26, 2017
    Assignee: PHOENIX MOLECULAR DESIGN
    Inventors: Sandra E. Dunn, Aarthi Jayanthan, Jaipal Reddy Nagireddy, Subhash Annedi, John H. Van Drie, Timothy S. Daynard, My-my Huynh
  • TETRAHYDROPYRIDO[3',2':4,5]PYRROLO[1,2-a]PYRAZINE-2-CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS
    Publication number: 20170240549
    Abstract: Described herein are carboxamide derivatives that are useful as inhibitors of p90 ribosomal S6 kinase (RSK), pharmaceutical compositions comprising the derivatives, and methods of using the derivatives in treating diseases or conditions associated with RSK activity.
    Type: Application
    Filed: February 17, 2017
    Publication date: August 24, 2017
    Inventors: Sandra E. DUNN, Aarthi JAYANTHAN, Jaipal Reddy NAGIREDDY, Subhash ANNEDI, John H. VAN DRIE, Timothy S. DAYNARD, My-my HUYNH
  • SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE
    Publication number: 20160235716
    Abstract: Compounds having a structure of Formula (IX): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1- - - -Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.
    Type: Application
    Filed: September 17, 2015
    Publication date: August 18, 2016
    Applicant: ABBVIE INC.
    Inventors: Edward A. Kesicki, Arthur F. Kluge, Michael A. Patane, John H. Van Drie, JR., Ce Wang, Maricel Torrent, Michael L. Curtin, Todd M. Hansen, Rick F. Clark, Robin R. Frey, Zhiqin Ji, Yujia Dai, William J. McClellan, Jane Gong, Gui-dong G. Zhu, Anthony Mastracchio, Michael R. Michaelides, Thomas D. Penning, Chunqiu C. Lai
  • INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
    Publication number: 20140010784
    Abstract: The present invention relates to peptidomimetic compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.
    Type: Application
    Filed: May 29, 2013
    Publication date: January 9, 2014
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Luc J. Farmer, Janos Pitlik, Robert B. Perni, John H. van Drie, JR.
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Patent number: 8486989
    Abstract: The present invention relates to peptidomimetic compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: July 16, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Luc J. Farmer, Robert B. Perni, Janos Pitlik, John H. van Drie, Jr.
  • INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
    Publication number: 20130116169
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Application
    Filed: June 7, 2012
    Publication date: May 9, 2013
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Robert B. Perni, John J. Court, Shawn D. Britt, Janos Pitlik, John H. van Drie
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Patent number: 8217048
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: July 10, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Robert B. Perni, John J. Court, Shawn D. Britt, Janos Pitlik, John H. van Drie
  • INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
    Publication number: 20110104115
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Application
    Filed: June 28, 2010
    Publication date: May 5, 2011
    Applicant: VERTEX PHARMACEUTICALS INCOROPRATED
    Inventors: Robert B. Perni, John J. Court, Shawn D. Britt, Janos Pitlik, John H. Van Drie
  • INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
    Publication number: 20100173851
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Application
    Filed: June 3, 2009
    Publication date: July 8, 2010
    Inventors: Janos Pitlik, Kevin M. Cottrell, Luc J. Farmer, Robert B. Perni, Lawrence F. Courtney, John H. van Drie, Mark A. Murcko
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Patent number: 7745444
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Grant
    Filed: April 10, 2008
    Date of Patent: June 29, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Robert B. Perni, John J. Court, Shawn D. Britt, Janos Pitlik, John H. van Drie
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Publication number: 20080311079
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Application
    Filed: April 10, 2008
    Publication date: December 18, 2008
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Robert B. Perni, John J. Court, Shawn D. Britt, Janos Pitlik, John H. van Drie
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Patent number: 7378422
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Grant
    Filed: September 7, 2004
    Date of Patent: May 27, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Robert B. Perni, John J. Court, Shawn D. Britt, Janos Pitlik, John H. van Drie
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Patent number: 7273885
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Grant
    Filed: April 11, 2003
    Date of Patent: September 25, 2007
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Janos Pitlik, Kevin M. Cottrell, Luc J. Farmer, Robert B. Perni, Lawrence F. Courtney, John H. van Drie, Mark A. Murcko